A Double-Blind Placebo-Controlled Trial of
Acediprol (Valproate Sodium) For Global
Severity in Child Autism Spectrum Disorders
Volume 2 - Issue 1
NA Aliyev1* and ZN Aliyev2
-
Author Information
Open or Close
- 1Department of psychiatry and addiction, Azerbaijan State Advanced Training Institute, Azerbaijan
- 2Department of psychiatry, Azerbaijan Medical University, Azerbaijan
*Corresponding author:
Nadir A Aliyev, Department of psychiatry and addiction, Azerbaijan State Advanced Training Institute, Baku,
Azerbaijan
Received: September 22, 2018; Published: September 28, 2018
DOI: 10.32474/OJNBD.2018.01.000127
Full Text
PDF
To view the Full Article Peer-reviewed Article PDF
Abstract
Objectives: The effects of Valproate sodium and placebo on global severity were compared in Child Autism Spectrum Disorders
(ASD).
Materials and Methods: Childs with ASDs were enrolled in a 12-week double-blind placebo-controlled Valproate sodium trial.
Fifty were randomly assigned to Valproate sodium (n=50) or placebo (n=50). The initial dose of Valproate sodium for children is
15mg/kg, then increases by 5-10mg/kg every week to 20-50mg/kg. Children are given 5% syrup (Sirupus Valproate sodium 5%), 1
ml 50mg. Repetitive behaviors were measured with the Clinical Global Impression (CGI) improvement scale.
Results: There was a significant treatment-by-time interaction indicating a significantly greater reduction in repetitive
behaviors across time for Valproate sodium than for placebo. With overall response defined as a CGI global improvement score of 2
or less, there were significantly more responders at week 12 in the Valproate sodium group than in the placebo group. The risk ratio
was 1.5 for CGI global improvement (responders: Valproate sodium, 80%; placebo, 12%). Side effects were not observed.
Conclusion: Valproate sodium treatment, compared to placebo, resulted in significantly greater improvement in global severity
behaviors, according to CGI rating scale. Valproate sodium appeared to be well tolerated movement score of 2 or less, there were
significantly more responders at week 12 in the Valproate sodium group than in the placebo group. The risk ratio was 1.5 for CGI
global improvement (responders: Acedipro, 80%; placebo, 12%). Side effects were not observed.
Abstract|
Introduction|
Materials and Methods|
Results |
Discussion |
Author Disclosure Information |
Acknowledgment |
References|